NATERA INC (Common Stock) – ticker 45E (NTRA) Insider Trading

Last 12 months

Insiders sold $397M and bought nothing on the open market.

87% of the selling was scheduled in advance under 10b5-1 plans. Director Roelof Botha sold $17.7M on Nov 24, 2025, 6.1% of their stake, outside a plan. The last open-market buy by an executive or director was in May 2022.

Net open-market

−$397M

0 buys · 121 sales

Under a 10b5-1 plan

87%

of the value sold

Insiders who bought / sold

0 / 12

executives and directors

Last open-market buy

May 2022

May 12, 2022

Get an email when NTRA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 16	Jonathan Sheena Director	Sold10b5-1 plan 12 parts	1,500	$402.47 average	$604k	0.6%	Form 4
Oct 15	Matthew Rabinowitz EXECUTIVE CHAIRMAN	Sold10b5-1 plan 19 parts	50,000	$402.64 average	$20.1M	2.3%	Form 4
Oct 1	Steven Leonard Chapman CEO AND PRESIDENT	Sold10b5-1 plan	1,273	$413.31	$526k	1.3%	Form 4
Oct 1	Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS	Sold10b5-1 plan 3 parts	3,000	$414.22 average	$1.24M	2.7%	Form 4
Sep 23	Jonathan Sheena Director	Sold10b5-1 plan 12 parts	18,064	$388.01 average	$7.01M	7.0%	Form 4
Sep 15 – 16	Jonathan Sheena Director	Sold10b5-1 plan 7 parts	9,150	$351.49 average	$3.22M	3.4%	Form 4
Sep 14 – 15	Matthew Rabinowitz EXECUTIVE CHAIRMAN	Sold10b5-1 plan 29 parts	102,000	$341.15 average	$34.8M	4.6%	Form 4
Sep 11	Matthew Rabinowitz EXECUTIVE CHAIRMAN	Sold10b5-1 plan 6 parts	50,000	$327.96 average	$16.4M	2.2%	Form 4
Sep 1 – 2	Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS	Sold10b5-1 plan 4 parts	18,160	$325.87 average	$5.92M	14%	Form 4
Sep 1	Steven Leonard Chapman CEO AND PRESIDENT	Sold10b5-1 plan	1,698	$320.99	$545k	1.7%	Form 4
Aug 10	John Fesko PRESIDENT, CHIEF BUS. OFFICER	Sold10b5-1 plan	6,517	$321.53	$2.1M	3.2%	Form 4
Aug 10	Jonathan Sheena Director	Sold10b5-1 plan	6,000	$325.32	$1.95M	2.2%	Form 4
Aug 7	Jonathan Sheena Director	Sold10b5-1 plan 10 parts	9,150	$315.66 average	$2.89M	3.2%	Form 4
Aug 7	Matthew Rabinowitz EXECUTIVE CHAIRMAN	Sold10b5-1 plan	2,000	$320.90	$642k	<0.1%	Form 4
Aug 3 – 4	Michael Burkes Brophy CHIEF FINANCIAL OFFICER	Sold10b5-1 plan 2 parts	795	$271.74 average	$216k	1.5%	Form 4
Aug 3	John Fesko PRESIDENT, CHIEF BUS. OFFICER	Sold10b5-1 plan	295	$267.99	$79k	0.2%	Form 4
Aug 3	Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS	Sold10b5-1 plan 7 parts	3,410	$265.58 average	$906k	2.6%	Form 4
Aug 3	Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER	Sold10b5-1 plan	334	$267.99	$90k	0.2%	Form 4
Aug 3	Steven Leonard Chapman CEO AND PRESIDENT	Sold10b5-1 plan 7 parts	3,076	$266.39 average	$819k	3.0%	Form 4
Aug 3	Jonathan Sheena Director	Sold10b5-1 plan	109	$267.99	$29k	<0.1%	Form 4
Aug 3	Matthew Rabinowitz EXECUTIVE CHAIRMAN	Sold10b5-1 plan	731	$267.99	$196k	<0.1%	Form 4
Jul 27 – 29	Michael Burkes Brophy CHIEF FINANCIAL OFFICER	Sold10b5-1 plan 5 parts	5,064	$253.29 average	$1.28M	8.8%	Form 4
Jul 27 – 28	John Fesko PRESIDENT, CHIEF BUS. OFFICER	Sold10b5-1 plan 2 parts	1,713	$257.00 average	$440k	0.9%	Form 4
Jul 27 – 28	Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS	Sold10b5-1 plan 2 parts	2,214	$257.00 average	$569k	1.6%	Form 4
Jul 27 – 28	Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER	Sold10b5-1 plan 2 parts	1,887	$257.08 average	$485k	1.1%	Form 4
Jul 27 – 28	Steven Leonard Chapman CEO AND PRESIDENT	Sold10b5-1 plan 2 parts	5,770	$256.51 average	$1.48M	5.3%	Form 4
Jul 27 – 28	Jonathan Sheena Director	Sold10b5-1 plan 2 parts	479	$257.93 average	$124k	0.2%	Form 4
Jul 27	Matthew Rabinowitz EXECUTIVE CHAIRMAN	Sold10b5-1 plan	1,718	$260.49	$448k	<0.1%	Form 4
Jul 15	Rowan E Chapman Director	Sold10b5-1 plan	135	$274.82	$37k	2.8%	Form 4
Jul 15	Jonathan Sheena Director	Sold10b5-1 plan 8 parts	1,500	$273.88 average	$411k	0.5%	Form 4
Jul 13	Jonathan Sheena Director	Sold10b5-1 plan 6 parts	3,150	$265.68 average	$837k	1.1%	Form 4
Jul 6	Matthew Rabinowitz EXECUTIVE CHAIRMAN	Sold10b5-1 plan	1,000	$280.00	$280k	<0.1%	Form 4
Jul 1	Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS	Sold10b5-1 plan 3 parts	3,000	$272.90 average	$819k	2.2%	Form 4
Jul 1	Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER	Sold10b5-1 plan 12 parts	16,800	$272.29 average	$4.57M	8.9%	Form 4
Jun 24	Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER	Sold10b5-1 plan 4 parts	33,600	$251.65 average	$8.46M	15%	Form 4
Jun 24	Herm Rosenman Director	Sold10b5-1 plan	16,530	$250.00	$4.13M	80%	Form 4
Jun 17	Jonathan Sheena Director	Sold10b5-1 plan 9 parts	1,500	$219.88 average	$330k	0.5%	Form 4
Jun 16	Rowan E Chapman Director	Sold10b5-1 plan	2,964	$216.78	$643k	49%	Form 4
Jun 15	Jonathan Sheena Director	Sold10b5-1 plan 4 parts	3,150	$211.14 average	$665k	1.1%	Form 4
Jun 12 – 15	Matthew Rabinowitz EXECUTIVE CHAIRMAN	Sold10b5-1 plan 21 parts	100,000	$214.47 average	$21.4M	4.2%	Form 4

Oct 1610b5-1 plan
Jonathan Sheena
Director · sold 1,500 at avg $402.47
$604k
0.6% of stake
Oct 1510b5-1 plan
Matthew Rabinowitz
EXECUTIVE CHAIRMAN · sold 50,000 at avg $402.64
$20.1M
2.3% of stake
Oct 110b5-1 plan
Steven Leonard Chapman
CEO AND PRESIDENT · sold 1,273 at $413.31
$526k
1.3% of stake
Oct 110b5-1 plan
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS · sold 3,000 at avg $414.22
$1.24M
2.7% of stake
Sep 2310b5-1 plan
Jonathan Sheena
Director · sold 18,064 at avg $388.01
$7.01M
7.0% of stake
Sep 15 – 1610b5-1 plan
Jonathan Sheena
Director · sold 9,150 at avg $351.49
$3.22M
3.4% of stake
Sep 14 – 1510b5-1 plan
Matthew Rabinowitz
EXECUTIVE CHAIRMAN · sold 102,000 at avg $341.15
$34.8M
4.6% of stake
Sep 1110b5-1 plan
Matthew Rabinowitz
EXECUTIVE CHAIRMAN · sold 50,000 at avg $327.96
$16.4M
2.2% of stake
Sep 1 – 210b5-1 plan
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS · sold 18,160 at avg $325.87
$5.92M
14% of stake
Sep 110b5-1 plan
Steven Leonard Chapman
CEO AND PRESIDENT · sold 1,698 at $320.99
$545k
1.7% of stake
Aug 1010b5-1 plan
John Fesko
PRESIDENT, CHIEF BUS. OFFICER · sold 6,517 at $321.53
$2.1M
3.2% of stake
Aug 1010b5-1 plan
Jonathan Sheena
Director · sold 6,000 at $325.32
$1.95M
2.2% of stake
Aug 710b5-1 plan
Jonathan Sheena
Director · sold 9,150 at avg $315.66
$2.89M
3.2% of stake
Aug 710b5-1 plan
Matthew Rabinowitz
EXECUTIVE CHAIRMAN · sold 2,000 at $320.90
$642k
<0.1% of stake
Aug 3 – 410b5-1 plan
Michael Burkes Brophy
CHIEF FINANCIAL OFFICER · sold 795 at avg $271.74
$216k
1.5% of stake
Aug 310b5-1 plan
John Fesko
PRESIDENT, CHIEF BUS. OFFICER · sold 295 at $267.99
$79k
0.2% of stake
Aug 310b5-1 plan
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS · sold 3,410 at avg $265.58
$906k
2.6% of stake
Aug 310b5-1 plan
Daniel Rabinowitz
SEC. AND CHIEF LEGAL OFFICER · sold 334 at $267.99
$90k
0.2% of stake
Aug 310b5-1 plan
Steven Leonard Chapman
CEO AND PRESIDENT · sold 3,076 at avg $266.39
$819k
3.0% of stake
Aug 310b5-1 plan
Jonathan Sheena
Director · sold 109 at $267.99
$29k
<0.1% of stake
Aug 310b5-1 plan
Matthew Rabinowitz
EXECUTIVE CHAIRMAN · sold 731 at $267.99
$196k
<0.1% of stake
Jul 27 – 2910b5-1 plan
Michael Burkes Brophy
CHIEF FINANCIAL OFFICER · sold 5,064 at avg $253.29
$1.28M
8.8% of stake
Jul 27 – 2810b5-1 plan
John Fesko
PRESIDENT, CHIEF BUS. OFFICER · sold 1,713 at avg $257.00
$440k
0.9% of stake
Jul 27 – 2810b5-1 plan
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS · sold 2,214 at avg $257.00
$569k
1.6% of stake
Jul 27 – 2810b5-1 plan
Daniel Rabinowitz
SEC. AND CHIEF LEGAL OFFICER · sold 1,887 at avg $257.08
$485k
1.1% of stake
Jul 27 – 2810b5-1 plan
Steven Leonard Chapman
CEO AND PRESIDENT · sold 5,770 at avg $256.51
$1.48M
5.3% of stake
Jul 27 – 2810b5-1 plan
Jonathan Sheena
Director · sold 479 at avg $257.93
$124k
0.2% of stake
Jul 2710b5-1 plan
Matthew Rabinowitz
EXECUTIVE CHAIRMAN · sold 1,718 at $260.49
$448k
<0.1% of stake
Jul 1510b5-1 plan
Rowan E Chapman
Director · sold 135 at $274.82
$37k
2.8% of stake
Jul 1510b5-1 plan
Jonathan Sheena
Director · sold 1,500 at avg $273.88
$411k
0.5% of stake
Jul 1310b5-1 plan
Jonathan Sheena
Director · sold 3,150 at avg $265.68
$837k
1.1% of stake
Jul 610b5-1 plan
Matthew Rabinowitz
EXECUTIVE CHAIRMAN · sold 1,000 at $280.00
$280k
<0.1% of stake
Jul 110b5-1 plan
Solomon Moshkevich
PRESIDENT, CLINICALDIAGNOSTICS · sold 3,000 at avg $272.90
$819k
2.2% of stake
Jul 110b5-1 plan
Daniel Rabinowitz
SEC. AND CHIEF LEGAL OFFICER · sold 16,800 at avg $272.29
$4.57M
8.9% of stake
Jun 2410b5-1 plan
Daniel Rabinowitz
SEC. AND CHIEF LEGAL OFFICER · sold 33,600 at avg $251.65
$8.46M
15% of stake
Jun 2410b5-1 plan
Herm Rosenman
Director · sold 16,530 at $250.00
$4.13M
80% of stake
Jun 1710b5-1 plan
Jonathan Sheena
Director · sold 1,500 at avg $219.88
$330k
0.5% of stake
Jun 1610b5-1 plan
Rowan E Chapman
Director · sold 2,964 at $216.78
$643k
49% of stake
Jun 1510b5-1 plan
Jonathan Sheena
Director · sold 3,150 at avg $211.14
$665k
1.1% of stake
Jun 12 – 1510b5-1 plan
Matthew Rabinowitz
EXECUTIVE CHAIRMAN · sold 100,000 at avg $214.47
$21.4M
4.2% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NTRA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Services-Medical Laboratories

FTREFortrea Holdings Inc.

RDNTRadNet Inc.

EXASExact Sciences Corp

GHGuardant Health Inc.

CAICaris Life Sciences, Inc.

VCYTVeracyte Inc.

CDNACareDx Inc.

BLLNBillionToOne, Inc.

Spot a number that looks wrong? Check it in NTRA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing NTRA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.